Phio Pharmaceuticals Corp. (PHIO) — SEC Filings
Phio Pharmaceuticals Corp. (PHIO) — 50 SEC filings. Latest: 8-K (Apr 8, 2026). Includes 36 8-K, 6 10-Q, 2 10-K.
View Phio Pharmaceuticals Corp. on SEC EDGAR
Overview
Phio Pharmaceuticals Corp. (PHIO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 8, 2026: Phio Pharmaceuticals Corp. filed an 8-K on April 8, 2026, to report the entry into a material definitive agreement. The filing includes financial statements and exhibits related to this agreement. Specific details of the agreement, including parties involved and financial terms, are not elaborated i
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bearish, 47 neutral, 1 mixed. The dominant filing sentiment for Phio Pharmaceuticals Corp. is neutral.
Filing Type Overview
Phio Pharmaceuticals Corp. (PHIO) has filed 36 8-K, 6 10-Q, 1 DEFA14A, 2 10-K, 2 S-1, 2 SC 13G/A, 1 DEF 14A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of PHIO's 45 recent filings, 2 were flagged as high-risk, 28 as medium-risk, and 15 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$2.392M |
| EPS | -$0.44 |
| Debt-to-Equity | 0.17 |
| Cash Position | $10.705M |
| Operating Margin | N/A |
| Total Assets | $11.505M |
| Total Debt | $1.666M |
Key Executives
- Dr. Michael H. Chang
- Dr. Michael J. Yudell
- Dr. David E. Epstein
- Robert J. Bitterman
Industry Context
Phio Pharmaceuticals operates in the highly competitive biotechnology sector, focusing on developing novel therapeutics. The industry is characterized by long development cycles, significant R&D investment, and high failure rates. Success often hinges on securing substantial funding for clinical trials and navigating complex regulatory pathways.
Top Tags
material-agreement (10) · filing (8) · equity-sale (7) · 8-k (6) · corporate-action (6) · sec-filing (5) · pharmaceuticals (5) · financials (5) · corporate-event (4) · Biotechnology (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and cash equivalents | $10.705M | Increased from $5.382M at December 31, 2024, providing a 12-month runway. |
| Net loss (Q3 2025) | $2.392M | Increased from $1.524M in Q3 2024, indicating widening losses. |
| Net loss (YTD Q3 2025) | $6.327M | Increased from $5.524M in YTD Q3 2024, reflecting higher operating expenses. |
| Research and development expenses (Q3 2025) | $1.181M | Increased from $644K in Q3 2024, showing significant investment in pipeline. |
| Research and development expenses (YTD Q3 2025) | $3.141M | Increased from $2.658M in YTD Q3 2024, demonstrating sustained R&D growth. |
| Net cash provided by financing activities (YTD Q3 2025) | $11.235M | Crucial for funding operations and alleviating going concern doubts. |
| Common shares outstanding | 10,764,428 | As of November 11, 2025, reflecting recent equity issuances. |
| Net proceeds from issuance of common stock and warrants (YTD Q3 2025) | $8.345M | Primary driver of increased cash and cash equivalents. |
| Common shares issued and outstanding | 5,784,770 | As of September 30, 2025, up from 1,733,717 at December 31, 2024, indicating significant dilution. |
| AgonOx reimbursement commitment | $4.000M | Terminated in May 2024, reducing future financial obligations. |
| SEC File Number | 001-36304 | Identifies the company's filing with the SEC. |
| I.R.S. Employer Identification No. | 45-3215903 | Company's tax identification number. |
| Net loss (Q2 2025) | $2.166M | Increased from $1.846M in Q2 2024, indicating widening losses. |
| Net loss (YTD Q2 2025) | $3.935M | Slightly improved from $4.000M in YTD Q2 2024. |
| Research and development expenses (Q2 2025) | $1.074M | Increased from $866K in Q2 2024, reflecting higher R&D investment. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Phio Pharmaceuticals Corp. (PHIO)?
Phio Pharmaceuticals Corp. has 50 recent SEC filings from Jan 2024 to Apr 2026, including 36 8-K, 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PHIO filings?
Across 50 filings, the sentiment breakdown is: 2 bearish, 47 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Phio Pharmaceuticals Corp. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Phio Pharmaceuticals Corp. (PHIO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Phio Pharmaceuticals Corp.?
Key financial highlights from Phio Pharmaceuticals Corp.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PHIO?
The investment thesis for PHIO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Phio Pharmaceuticals Corp.?
Key executives identified across Phio Pharmaceuticals Corp.'s filings include Dr. Michael H. Chang, Dr. Michael J. Yudell, Dr. David E. Epstein, Robert J. Bitterman.
What are the main risk factors for Phio Pharmaceuticals Corp. stock?
Of PHIO's 45 assessed filings, 2 were flagged high-risk, 28 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Phio Pharmaceuticals Corp.?
Forward guidance and predictions for Phio Pharmaceuticals Corp. are extracted from SEC filings as they are enriched.